Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19 Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has led to worldwide efforts to understand the biological traits of the newly identified human coronavirus (HCoV-19) virus. In this mass spectrometry (MS)-based study, we reveal that out of 21 possible glycosites in the HCoV-19 spike protein (S protein), 20 are completely occupied by N-glycans, predominantly of the oligomannose type. All seven glycosylation sites in human angiotensin I converting enzyme 2 (hACE2) were found to be completely occupied, mainly by complex N-glycans. However, glycosylation did not directly contribute to the binding affinity between HCoV-19 S protein and hACE2. Additional post-translational modification (PTM) was identified, including multiple methylated sites in both proteins and multiple sites with hydroxylproline in hACE2. Refined structural models of HCoV-19 S protein and hACE2 were built by adding N-glycan and PTMs to recently published cryogenic electron microscopy structures. The PTM and glycan maps of HCoV-19 S protein and hACE2 provide additional structural details for studying the mechanisms underlying host attachment and the immune response of HCoV-19, as well as knowledge for developing desperately needed remedies and vaccines.

Keywords

N-glycosylation / COVID-19 / Spike protein / hACE2 / Structure

References

[[1]] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–9.

[[2]] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID19 in real time. Lancet Infect Dis 2020;20(5):533–4.

[[3]] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.

[[4]] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.

[[5]] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.

[[6]] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061–9.

[[7]] Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol 2020;30(7):1346–51.

[[8]] Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV). Cell Host Microbe 2020;27:325–8.

[[9]] Xu Y. Unveiling the origin and transmission of 2019-nCoV. Trends Microbiol 2020;28(4):239–40.

[[10]] Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell 2020;181(2):223–7.

[[11]] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94(7):e00127–220.

[[12]] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–80.e8.

[[13]] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181 (2):281–92.e6.

[[14]] Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367(6483):1260–3.

[[15]] Fukushi M, Yoshinaka Y, Matsuoka Y, Hatakeyama S, Ishizaka Y, Kirikae T, et al. Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus. J Virol 2012;86(21):11745–53.

[[16]] de Groot RJ. Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses. Glycoconj J 2006;23(1–2):59–72.

[[17]] Raman R, Tharakaraman K, Sasisekharan V, Sasisekharan R. Glycan-protein interactions in viral pathogenesis. Curr Opin Struct Biol 2016;40:153–62.

[[18]] Chang D, Zaia J. Why glycosylation matters in building a better flu vaccine. Mol Cell Proteomics 2019;18(12):2348–58.

[[19]] Li W, Hulswit RJG, Widjaja I, Raj VS, McBride R, Peng W, et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. PNAS 2017;114(40):E8508–17.

[[20]] Parsons LM, Bouwman KM, Azurmendi H, de Vries RP, Cipollo JF, Verheije MH. Glycosylation of the viral attachment protein of avian coronavirus is essential for host cell and receptor binding. J Biol Chem 2019;294:7797–809.

[[21]] Shih YP, Chen CY, Liu SJ, Chen KH, Lee YM, Chao YC, et al. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J Virol 2006;80(21):10315–24.

[[22]] York IA, Stevens J, Alymova IV. Influenza virus N-linked glycosylation and innate immunity. Biosci Rep 2018;39(1):BSR20171505.

[[23]] Zheng J, Yamada Y, Fung TS, Huang M, Chia R, Liu DX. Identification of N-linked glycosylation sites in the spike protein and their functional impact on the replication and infectivity of coronavirus infectious bronchitis virus in cell culture. Virology 2018;513:65–74.

[[24]] Zhou Y, Lu K, Pfefferle S, Bertram S, Glowacka I, Drosten C, et al. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J Virol 2010;84(17):8753–64.

[[25]] Han DP, Lohani M, Cho MW. Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J Virol 2007;81(21):12029–39.

[[26]] Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. PNAS 2004;101(44):15748–53.

[[27]] Zheng L, Li H, Fu L, Liu S, Yan Q, Leng SX. Blocking cellular N-glycosylation suppresses human cytomegalovirus entry in human fibroblasts. Microb Pathog 2020;138:103776.

[[28]] Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.

[[29]] Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccines Immunother 2014;10(3):648–58.

[[30]] Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). VirusDisease 2020;31:13–21.

[[31]] Sun Z, Liu X, Jiang J, Huang H, Wang J, Wu D, et al. Toward biomarker development in large clinical cohorts: an integrated high-throughput 96-wellplate-based sample preparation workflow for versatile downstream proteomic analyses. Anal Chem 2016;88(17):8518–25.

[[32]] Liu MQ, Zeng WF, Fang P, Cao WQ, Liu C, Yan GQ, et al. pGlyco 2.0 enables precision N-glycoproteomics with comprehensive quality control and one-step mass spectrometry for intact glycopeptide identification. Nat Commun 2017;8:438.

[[33]] Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr 2010;D66:486–501.

[[34]] Bailey UM, Jamaluddin MF, Schulz BL. Analysis of congenital disorder of glycosylation-Id in a yeast model system shows diverse site-specific underglycosylation of glycoproteins. J Proteome Res 2012;11:5376–83.

[[35]] Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and Oglycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology 2020;30(12):981–8.

[[36]] Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 2020;369(6501):330–3.

[[37]] Krokhin O, Li Y, Andonov A, Feldmann H, Flick R, Jones S, et al. Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. Mol Cell Proteomics 2003;2(5):346–56.

[[38]] Ying W, Hao Y, Zhang Y, Peng W, Qin E, Cai Y, et al. Proteomic analysis on structural proteins of severe acute respiratory syndrome coronavirus. Proteomics 2004;4(2):492–504.

[[39]] Song HC, Seo MY, Stadler K, Yoo BJ, Choo QL, Coates SR, et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol 2004;78 (19):10328–35.

[[40]] Watanabe Y, Bowden TA, Wilson IA, Crispin M. Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta Gen Subj 2019;1863 (10):1480–97.

[[41]] Feldmann H, Nichol ST, Klenk HD, Peters CJ, Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 1994;199(2):469–73.

[[42]] Ritchie G, Harvey DJ, Feldmann F, Stroeher U, Feldmann H, Royle L, et al. Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. Virology 2010;399(2):257–69.

[[43]] Yang TJ, Chang YC, Ko TP, Draczkowski P, Chien YC, Chang YC, et al. Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans. PNAS 2020;117(3):1438–46.

[[44]] Vigerust DJ, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 2007;15(5):211–8.

[[45]] Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H, Dutta S. Emergence of novel coronavirus and COVID-19: whether to stay or die out? Crit Rev Microbiol 2020;46(2):182–93.

[[46]] Robinson BS, Arthur CM, Evavold B, Roback E, Kamili NA, Stowell CS, et al. The sweet-side of leukocytes: galectins as master regulators of neutrophil function. Front Immunol 2019;53(6):925–35.

[[47]] Wang WH, Lin CY, Chang MR, Urbina AN, Assavalapsakul W, Thitithanyanont A, et al. The role of galectins in virus infection—a systemic literature review. J Microbiol Immunol Infect 2019;53(6):925–35.

[[48]] Cheng Y, Cheng G, Chui CH, Lau FY, Chan PK, Ng MH, et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005;293 (12):1450–1.

[[49]] Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO blood group and the COVID-19 susceptibility. Clin Infect Dis 2020;73(2):328– 31.

[[50]] Guillon P, Clément M, Sébille V, Rivain JG, Chou CF, Ruvoën-Clouet N, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology 2008;18 (12):1085–93.

[[51]] Zhao X, Guo F, Comunale MA, Mehta A, Sehgal M, Jain P, et al. Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrob Agents Chemother 2015;59(1):206–16.

[[52]] Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 2020;6:16.